Fact sheet updated May 2018

Genmab

To improve the lives of patients by creating & developing innovative antibody products

2 marketed products

DARZALEX® marketed in the US, Europe, Japan & other countries
Arzerra® marketed globally[1]

2 proprietary technologies

DuoBody® bispecific platform
HexaBody® technology

~20 pre-clinical projects

Extensive partnered & own pre-clinical pipeline incl. DuoBody-CD40x4-1BB

Solid financial base

Allows for building capabilities to market own product in future

4 proprietary clinical programs

Tisotumab vedotin, HuMax®-AXL-ADC, HexaBody-DR5/DR5, DuoBody-CD3xCD20

2 categories of cancer

Generate products to treat both solid tumors & hematological cancers

3 office locations

Facilities in Denmark, the Netherlands & USA

28 INDs

Investigational new drug applications filed by Genmab & partners in 18 years

DKK
63B
~USD 10.5 M[2]
2017 year end market cap

DKK
1,021M
~USD 170.2M[2]
2017 operating expenses
34% increase versus 2016

DKK
2,365M
~USD 394.2[2]
2017 revenue
30% increase versus 2016

DKK
5,423M
~USD 903.8M[2]
2017 year end cash position

Operating Result
MDKK (~MUSD[2])



2018 Guidance

Income Statement	DKKM	USDM[2]
Revenue	2,700 – 3,100	450 - 517
Operating expenses	(1,400) – (1,600)	(233) – (267)
Operating income	1,300 – 1,500	217 - 250

[2]USD 1.00 = DKK 6.00

Our Three-pronged Strategy
Focus on core competence
Turn science into medicine
Build a profitable & successful biotech

Our Vision
By 2025, our own product has transformed cancer treatment and we have a pipeline of knock-your-socks-off antibodies

Executive Management:

Jan G. J. van de Winkel
Ph.D. President & CEO

David A. Eatwell FCCA
Executive Vice President & CFO

Judith Klimovsky M.D.
Executive Vice President & CDO

Founded: 1999, IPO: 2000
Exchange: NASDAQ OMX Copenhagen A/S

Symbol:
GEN

ADR ticker Symbol:

GMXAY

Stock information as of May 8 2018:

Market cap:
~DKK 80 Bn (~USD 12,810 M)

Shares outstanding:
61,281,242

[1]See Arzerra "At-A-Glance" on following page for additional information

For more information: genmab.com or contact: Rachel Curtis Gravesen, Senior Vice President, Investor Relations & Communications (rcg@genmab.com)

Robust Product Pipeline and Passion for Innovation

Development for Marketed & Genmab Proprietary Products

Product		Disease Indications	Development Phase: Pre-clinical	I	I/II	II	III
Daratumumab	BTD	Multiple myeloma (MM)					
Target: CD38, Partner: Janssen	(2 – MM)	Amyloidosis					
		Non-MM & Solid tumors					
Ofatumumab (OMB157)	BTD	Follicular lymphoma (FL) (IV)					
Target: CD20, Partner: Novartis	(CLL)	Relapsing multiple sclerosis (RMS) (SubQ)					
Tisotumab vedotin		Solid tumors					
Target: TF, Partner: Seattle Genetics							
HuMax-AXL-ADC		Solid tumors					
Target: AXL							
HexaBody-DR5/DR5[4]		Solid tumors					
Target: DR5							
DuoBody-CD3xCD20[4]		Hematological malignancies					
Targets: CD20, CD3							
Additional Shots on Goal							
Teprotumumab (RV001)	BTD	Graves' orbitopathy					
Target: IGF-1R, Partner: River Vision							
HuMax-IL8		Advanced cancers					
Target: IL8, Partner: BMS							
ADCT-301 (HuMax-TAC-ADC)		Lymphoma					
Target: CD25, Partner: ADCT		Acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL)					
JNJ-61186372		Non-small-cell lung cancer (NSCLC)					
Targets: EGFR, cMET, Partner: Janssen							
JNJ-63709178		AML					
Targets: CD3, CD123, Partner: Janssen							
JNJ-64007957		Relapsed or refractory MM					
Targets: BCMA, CD3, Partner: Janssen							
JNJ-64407564		Relapsed or refractory MM					
Targets: CD3,GPRC5D, Partner: Janssen							
~20 Active Pre-clinical programs incl., DuoBody-CD40x4-1BB		Proprietary programs: HuMab, HuMab-ADC, DuoBody, DuoBody-ADC & HexaBody					
		Partnered programs: HuMab, DuoBody & HexaBody					

[4] Announced but not yet started

Products in development: Daratumumab, Ofatumumab, Tisotumab vedotin, HuMax-AXL-ADC, HexaBody-DR5/DR5, DuoBody-CD3xCD20, Pre-clinical programs, Technologies

At-A-Glance – SELECTED PRODUCTS

DARZALEX® (daratumumab)[3]
- First-in-class CD38 antibody in dev. to treat cancer
- Approved in combo. w/ other therapies in relapsed/refractory MM in U.S., EU & Japan; as monotherapy for heavily pretreated or double-refractory multiple myeloma in U.S. & EU; in combo w/ VMP for newly diagnosed MM in U.S.
- Multiple Phase III studies ongoing or announced in MM & amyloidosis
- Early stage studies ongoing in solid tumors & other indications
- Subcutaneous formulation in development
- Collaboration with Janssen
- 2017 net sales reported by Janssen; $1,242M

Tisotumab vedotin
- Antibody-drug conjugate (ADC, antibody coupled to a cell-killing agent) in dev. to treat solid tumors
- Ph II study in cervical cancer announced; two Phase I/II clinical studies in solid tumors ongoing
- 50:50 co-development with Seattle Genetics

HuMax®-AXL-ADC
- ADC in development to treat solid tumors
- Ph I/II clinical study for six types of solid tumors ongoing

DuoBody-CD3xCD20
- Proprietary bispecific antibody created with Genmab's DuoBody technology
- Phase I/II clinical trial in B-cell malignancies anticipated to start in 2018

Arzerra® (ofatumumab)[3]
- Human CD20 antibody in dev. to treat cancer & autoimmune disease
- Approved in certain territories for certain CLL indications. On January 22, 2018 announced that Novartis intends to transition Arzerra from commercial availability to limited availability via compassionate use programs in non-US markets.
- 2 Ph III studies w/ low dose subcutaneous in relapsing multiple sclerosis ongoing
- Collaboration with Novartis

HexaBody-DR5/DR5
- Proprietary antibody therapeutic created with Genmab's HexaBody technology
- Composed of two non-competing HexaBody molecules that target two distinct DR5 epitopes
- Phase I/II clinical trial in solid tumors anticipated to start in 2018

Pre-Clinical Programs
- Broad pre-clinical pipeline of >20 programs including DuoBody-CD40x4-1BB
- Pre-clinical pipeline includes both partnered products & in-house programs based on our proprietary technologies
- Multiple INDs expected to be submitted over coming years

[3] See local country prescribing information for precise indications

TECHNOLOGIES

DuoBody® Platform
- Genmab's proprietary bispecific antibody tech.
- Generates bispecific antibodies that can bind to two targets or different epitopes on one target
- Potential application in cancer, autoimmune, infectious, cardiovascular, CNS diseases & hemophilia
- Multiple ongoing commercial & research collaborations

Antibody-Drug Conjugates
- Monoclonal antibodies w/ potent toxic agents coupled to them
- Expanding development area or cancer immunotherapy

HexaBody® Technology
- Genmab's proprietary technology designed to increase the potency of antibodies
- Potential application in cancer and infectious diseases
- Broadly applicable tech. that builds on natural antibody biology

Antibody Generation Technology Platforms
- UltiMab transgenic mouse technology
- OmniAb transgenic mouse & rat platforms
- MAB Discovery's rabbit antibody platform

This document contains forward looking statements that involve significant risks and uncertainties. Discussion of which can be found in Genmab's annual report at genmab.com. v08052018